Back to Search Start Over

Glucose-driven histone lactylation promotes the immunosuppressive activity of monocyte-derived macrophages in glioblastoma.

Authors :
De Leo A
Ugolini A
Yu X
Scirocchi F
Scocozza D
Peixoto B
Pace A
D'Angelo L
Liu JKC
Etame AB
Rughetti A
Nuti M
Santoro A
Vogelbaum MA
Conejo-Garcia JR
Rodriguez PC
Veglia F
Source :
Immunity [Immunity] 2024 May 14; Vol. 57 (5), pp. 1105-1123.e8. Date of Electronic Publication: 2024 May 03.
Publication Year :
2024

Abstract

Immunosuppressive macrophages restrict anti-cancer immunity in glioblastoma (GBM). Here, we studied the contribution of microglia (MGs) and monocyte-derived macrophages (MDMs) to immunosuppression and mechanisms underlying their regulatory function. MDMs outnumbered MGs at late tumor stages and suppressed T cell activity. Molecular and functional analysis identified a population of glycolytic MDM expressing GLUT1 with potent immunosuppressive activity. GBM-derived factors promoted high glycolysis, lactate, and interleukin-10 (IL-10) production in MDMs. Inhibition of glycolysis or lactate production in MDMs impaired IL-10 expression and T cell suppression. Mechanistically, intracellular lactate-driven histone lactylation promoted IL-10 expression, which was required to suppress T cell activity. GLUT1 expression on MDMs was induced downstream of tumor-derived factors that activated the PERK-ATF4 axis. PERK deletion in MDM abrogated histone lactylation, led to the accumulation of intratumoral T cells and tumor growth delay, and, in combination with immunotherapy, blocked GBM progression. Thus, PERK-driven glucose metabolism promotes MDM immunosuppressive activity via histone lactylation.<br />Competing Interests: Declaration of interests The authors declare no competing interests.<br /> (Copyright © 2024 Elsevier Inc. All rights reserved.)

Details

Language :
English
ISSN :
1097-4180
Volume :
57
Issue :
5
Database :
MEDLINE
Journal :
Immunity
Publication Type :
Academic Journal
Accession number :
38703775
Full Text :
https://doi.org/10.1016/j.immuni.2024.04.006